A Phase 1 Study of MLN8237, an Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
The purpose of this study is to learn if the study drug (MLN8237) is effective in treating solid tumors when used in combination with a standard docetaxel regimen and to find the maxiumum tolerated dose for these drugs, when used together.
Multiple disease sites
* Subject should have a diagnosis of histologically or cytologically confirmed advanced solid tumor.
* Subject must have measureable or evaluable disease with progressing or persistent disease.
18 - 99
Healthy Volunteers Needed
Duration of Participation
Clinical Trials Information Line: Phone 503-494-1080 or firstname.lastname@example.org
Millennium Pharmaceuticals, Inc.